Carmustine

Carmustine is a chemotherapy medication used in the treatment of various cancers, including brain tumors, multiple myeloma, and lymphoma. It belongs to the class of drugs known as alkylating agents, which work by interfering with the DNA replication process in cancer cells.

Indications

-Brain tumors (e.g., gliomas) -Multiple myeloma -Lymphomas (e.g., Hodgkin’s lymphoma) -Other cancers as determined by a healthcare provider

Dosage

-Adults: Typically administered intravenously. Dosage varies based on the type of cancer, patient’s condition, and response to treatment. Common doses include 150-200 mg/m² administered every 6 weeks. -Children: Dosage is adjusted according to body weight and the specific condition being treated.

Contra-Indications

-Hypersensitivity to Carmustine or any of its components -Severe liver dysfunction -Severe renal impairment -Pregnancy (Category D) and lactation (due to potential harm to the fetus or infant)

Special Precautions

-Monitor for signs of bone marrow suppression, liver toxicity, and kidney dysfunction. -Regular blood tests are required to check for potential side effects such as leukopenia or thrombocytopenia. -Use with caution in patients with pre-existing liver or kidney disease.

Side Effects

-Common: Nausea, vomiting, loss of appetite, diarrhea -Severe: Myelosuppression (e.g., low blood cell counts), pulmonary fibrosis, liver toxicity, kidney damage -Rare: Allergic reactions, secondary cancers